Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Developmental Regulation of KCC2 Phosphorylation Has Long-Term Impacts on Cognitive Function.

Moore YE, Conway LC, Wobst HJ, Brandon NJ, Deeb TZ, Moss SJ.

Front Mol Neurosci. 2019 Jul 23;12:173. doi: 10.3389/fnmol.2019.00173. eCollection 2019.

2.

Identification of a Core Amino Acid Motif within the α Subunit of GABAARs that Promotes Inhibitory Synaptogenesis and Resilience to Seizures.

Nathanson AJ, Zhang Y, Smalley JL, Ollerhead TA, Rodriguez Santos MA, Andrews PM, Wobst HJ, Moore YE, Brandon NJ, Hines RM, Davies PA, Moss SJ.

Cell Rep. 2019 Jul 16;28(3):670-681.e8. doi: 10.1016/j.celrep.2019.06.014.

3.

SAR inspired by aldehyde oxidase (AO) metabolism: Discovery of novel, CNS penetrant tricyclic M4 PAMs.

Chopko TC, Han C, Gregro AR, Engers DW, Felts AS, Poslusney MS, Bollinger KA, Morrison RD, Bubser M, Lamsal A, Luscombe VB, Cho HP, Schnetz-Boutaud NC, Rodriguez AL, Chang S, Daniels JS, Stec DF, Niswender CM, Jones CK, Wood MR, Wood MW, Duggan ME, Brandon NJ, Conn PJ, Bridges TM, Lindsley CW, Melancon BJ.

Bioorg Med Chem Lett. 2019 Aug 15;29(16):2224-2228. doi: 10.1016/j.bmcl.2019.06.032. Epub 2019 Jun 20.

PMID:
31248774
4.

Comprehensive assessment of multiple biases in small RNA sequencing reveals significant differences in the performance of widely used methods.

Wright C, Rajpurohit A, Burke EE, Williams C, Collado-Torres L, Kimos M, Brandon NJ, Cross AJ, Jaffe AE, Weinberger DR, Shin JH.

BMC Genomics. 2019 Jun 21;20(1):513. doi: 10.1186/s12864-019-5870-3.

5.

Tool inhibitors and assays to interrogate the biology of the TRAF2 and NCK interacting kinase.

Read J, Collie IT, Nguyen-McCarty M, Lucaj C, Robinson J, Conway L, Mukherjee J, McCall E, Donohoe G, Flavell E, Peciak K, Warwicker J, Dix C, Van den Hoven BG, Madin A, Brown DG, Moss S, Haggarty SJ, Brandon NJ, Bürli RW.

Bioorg Med Chem Lett. 2019 Aug 1;29(15):1962-1967. doi: 10.1016/j.bmcl.2019.05.032. Epub 2019 May 18.

PMID:
31153805
6.

VU6005806/AZN-00016130, an advanced M4 positive allosteric modulator (PAM) profiled as a potential preclinical development candidate.

Engers DW, Melancon BJ, Gregro AR, Bertron JL, Bollinger SR, Felts AS, Konkol LC, Wood MR, Bollinger KA, Luscombe VB, Rodriguez AL, Jones CK, Bubser M, Yohn SE, Wood MW, Brandon NJ, Dugan ME, Niswender CM, Jeffrey Conn P, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2019 Jul 15;29(14):1714-1718. doi: 10.1016/j.bmcl.2019.05.026. Epub 2019 May 16.

PMID:
31113706
7.

PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.

Whiteley EL, Tejeda GS, Baillie GS, Brandon NJ.

Cell Signal. 2019 Aug;60:31-38. doi: 10.1016/j.cellsig.2019.04.001. Epub 2019 Apr 2. Review.

PMID:
30951862
8.

Schizophrenia risk variants influence multiple classes of transcripts of sorting nexin 19 (SNX19).

Ma L, Semick SA, Chen Q, Li C, Tao R, Price AJ, Shin JH, Jia Y; BrainSeq Consortium, Brandon NJ, Cross AJ, Hyde TM, Kleinman JE, Jaffe AE, Weinberger DR, Straub RE.

Mol Psychiatry. 2019 Jan 11. doi: 10.1038/s41380-018-0293-0. [Epub ahead of print]

PMID:
30635639
9.

Potentiating KCC2 activity is sufficient to limit the onset and severity of seizures.

Moore YE, Deeb TZ, Chadchankar H, Brandon NJ, Moss SJ.

Proc Natl Acad Sci U S A. 2018 Oct 2;115(40):10166-10171. doi: 10.1073/pnas.1810134115. Epub 2018 Sep 17.

10.

Novel inhibitors of As(III) S-adenosylmethionine methyltransferase (AS3MT) identified by virtual screening.

Bürli RW, Wei H, Ernst G, Mariga A, Hardern IM, Herlihy K, Cross AJ, Wesolowski SS, Chen H, McKay RDG, Weinberger DR, Brandon NJ, Barrow JC.

Bioorg Med Chem Lett. 2018 Oct 15;28(19):3231-3235. doi: 10.1016/j.bmcl.2018.08.012. Epub 2018 Aug 14.

PMID:
30170942
11.

Developmental seizures and mortality result from reducing GABAA receptor α2-subunit interaction with collybistin.

Hines RM, Maric HM, Hines DJ, Modgil A, Panzanelli P, Nakamura Y, Nathanson AJ, Cross A, Deeb T, Brandon NJ, Davies P, Fritschy JM, Schindelin H, Moss SJ.

Nat Commun. 2018 Aug 7;9(1):3130. doi: 10.1038/s41467-018-05481-1.

12.

Corrigendum to "Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides" [Bioorg. Med. Chem. Lett. 27(23) (2017) 5179-5184].

Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2018 Sep 15;28(17):3014. doi: 10.1016/j.bmcl.2018.07.022. Epub 2018 Jul 31. No abstract available.

13.

Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis.

Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, Kam-Thong T, Xi HS, Quan J, Chen Q, Colantuoni C, Ulrich WS, Maher BJ, Deep-Soboslay A; BrainSeq Consortium, Cross AJ, Brandon NJ, Leek JT, Hyde TM, Kleinman JE, Weinberger DR.

Nat Neurosci. 2018 Aug;21(8):1117-1125. doi: 10.1038/s41593-018-0197-y. Epub 2018 Jul 26.

14.

Locally Reducing KCC2 Activity in the Hippocampus is Sufficient to Induce Temporal Lobe Epilepsy.

Kelley MR, Cardarelli RA, Smalley JL, Ollerhead TA, Andrew PM, Brandon NJ, Deeb TZ, Moss SJ.

EBioMedicine. 2018 Jun;32:62-71. doi: 10.1016/j.ebiom.2018.05.029. Epub 2018 Jun 5.

15.

Small molecule inducers of ABCA1 and apoE that act through indirect activation of the LXR pathway.

Fan J, Zhao RQ, Parro C, Zhao W, Chou HY, Robert J, Deeb TZ, Raynoschek C, Barichievy S, Engkvist O, Maresca M, Hicks R, Meuller J, Moss SJ, Brandon NJ, Wood MW, Kulic I, Wellington CL.

J Lipid Res. 2018 May;59(5):830-842. doi: 10.1194/jlr.M081851. Epub 2018 Mar 21.

16.

The small molecule CLP257 does not modify activity of the K+-Cl- co-transporter KCC2 but does potentiate GABAA receptor activity.

Cardarelli RA, Jones K, Pisella LI, Wobst HJ, McWilliams LJ, Sharpe PM, Burnham MP, Baker DJ, Chudotvorova I, Guyot J, Silayeva L, Morrow DH, Dekker N, Zicha S, Davies PA, Holenz J, Duggan ME, Dunlop J, Mather RJ, Wang Q, Medina I, Brandon NJ, Deeb TZ, Moss SJ.

Nat Med. 2017 Dec 7;23(12):1394-1396. doi: 10.1038/nm.4442. No abstract available.

PMID:
29216042
17.

Molecular architecture of potassium chloride co-transporter KCC2.

Agez M, Schultz P, Medina I, Baker DJ, Burnham MP, Cardarelli RA, Conway LC, Garnier K, Geschwindner S, Gunnarsson A, McCall EJ, Frechard A, Audebert S, Deeb TZ, Moss SJ, Brandon NJ, Wang Q, Dekker N, Jawhari A.

Sci Rep. 2017 Nov 28;7(1):16452. doi: 10.1038/s41598-017-15739-1.

18.

X-ray Characterization and Structure-Based Optimization of Striatal-Enriched Protein Tyrosine Phosphatase Inhibitors.

Witten MR, Wissler L, Snow M, Geschwindner S, Read JA, Brandon NJ, Nairn AC, Lombroso PJ, Käck H, Ellman JA.

J Med Chem. 2017 Nov 22;60(22):9299-9319. doi: 10.1021/acs.jmedchem.7b01292. Epub 2017 Nov 8.

19.

Verbal working memory and functional large-scale networks in schizophrenia.

Dauvermann MR, Moorhead TW, Watson AR, Duff B, Romaniuk L, Hall J, Roberts N, Lee GL, Hughes ZA, Brandon NJ, Whitcher B, Blackwood DH, McIntosh AM, Lawrie SM.

Psychiatry Res Neuroimaging. 2017 Dec 30;270:86-96. doi: 10.1016/j.pscychresns.2017.10.004. Epub 2017 Oct 23.

20.

N-Ethylmaleimide increases KCC2 cotransporter activity by modulating transporter phosphorylation.

Conway LC, Cardarelli RA, Moore YE, Jones K, McWilliams LJ, Baker DJ, Burnham MP, Bürli RW, Wang Q, Brandon NJ, Moss SJ, Deeb TZ.

J Biol Chem. 2017 Dec 29;292(52):21253-21263. doi: 10.1074/jbc.M117.817841. Epub 2017 Nov 1.

21.

Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and biological characterization of a series of azetidine-derived tertiary amides.

Tarr JC, Wood MR, Noetzel MJ, Melancon BJ, Lamsal A, Luscombe VB, Rodriguez AL, Byers FW, Chang S, Cho HP, Engers DW, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2017 Dec 1;27(23):5179-5184. doi: 10.1016/j.bmcl.2017.10.053. Epub 2017 Oct 24. Erratum in: Bioorg Med Chem Lett. 2018 Sep 15;28(17):3014.

22.

Estradiol modulates the efficacy of synaptic inhibition by decreasing the dwell time of GABAA receptors at inhibitory synapses.

Mukherjee J, Cardarelli RA, Cantaut-Belarif Y, Deeb TZ, Srivastava DP, Tyagarajan SK, Pangalos MN, Triller A, Maguire J, Brandon NJ, Moss SJ.

Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11763-11768. doi: 10.1073/pnas.1705075114. Epub 2017 Oct 16.

23.

Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.

Schülke JP, Brandon NJ.

Adv Neurobiol. 2017;17:15-43. doi: 10.1007/978-3-319-58811-7_2. Review.

PMID:
28956328
24.

Seizing Control of KCC2: A New Therapeutic Target for Epilepsy.

Moore YE, Kelley MR, Brandon NJ, Deeb TZ, Moss SJ.

Trends Neurosci. 2017 Sep;40(9):555-571. doi: 10.1016/j.tins.2017.06.008. Epub 2017 Aug 10. Review.

PMID:
28803659
25.

Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154.

Gould RW, Grannan MD, Gunter BW, Ball J, Bubser M, Bridges TM, Wess J, Wood MW, Brandon NJ, Duggan ME, Niswender CM, Lindsley CW, Conn PJ, Jones CK.

Neuropharmacology. 2018 Jan;128:492-502. doi: 10.1016/j.neuropharm.2017.07.013. Epub 2017 Jul 17.

PMID:
28729220
26.

FBXW7 regulates DISC1 stability via the ubiquitin-proteosome system.

Yalla K, Elliott C, Day JP, Findlay J, Barratt S, Hughes ZA, Wilson L, Whiteley E, Popiolek M, Li Y, Dunlop J, Killick R, Adams DR, Brandon NJ, Houslay MD, Hao B, Baillie GS.

Mol Psychiatry. 2018 May;23(5):1278-1286. doi: 10.1038/mp.2017.138. Epub 2017 Jul 20.

27.

Challenges in the development of an M4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides.

Tarr JC, Wood MR, Noetzel MJ, Bertron JL, Weiner RL, Rodriguez AL, Lamsal A, Byers FW, Chang S, Cho HP, Jones CK, Niswender CM, Wood MW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2017 Jul 1;27(13):2990-2995. doi: 10.1016/j.bmcl.2017.05.014. Epub 2017 May 6.

28.

Truncation of the TAR DNA-binding protein 43 is not a prerequisite for cytoplasmic relocalization, and is suppressed by caspase inhibition and by introduction of the A90V sequence variant.

Wobst HJ, Delsing L, Brandon NJ, Moss SJ.

PLoS One. 2017 May 16;12(5):e0177181. doi: 10.1371/journal.pone.0177181. eCollection 2017.

29.

Altered expression of histamine signaling genes in autism spectrum disorder.

Wright C, Shin JH, Rajpurohit A, Deep-Soboslay A, Collado-Torres L, Brandon NJ, Hyde TM, Kleinman JE, Jaffe AE, Cross AJ, Weinberger DR.

Transl Psychiatry. 2017 May 9;7(5):e1126. doi: 10.1038/tp.2017.87.

30.

Optimization of M4 positive allosteric modulators (PAMs): The discovery of VU0476406, a non-human primate in vivo tool compound for translational pharmacology.

Melancon BJ, Wood MR, Noetzel MJ, Nance KD, Engelberg EM, Han C, Lamsal A, Chang S, Cho HP, Byers FW, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Wu D, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2017 Jun 1;27(11):2296-2301. doi: 10.1016/j.bmcl.2017.04.043. Epub 2017 Apr 13.

31.

Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS In vitro.

Wobst HJ, Wesolowski SS, Chadchankar J, Delsing L, Jacobsen S, Mukherjee J, Deeb TZ, Dunlop J, Brandon NJ, Moss SJ.

Front Mol Neurosci. 2017 Feb 24;10:46. doi: 10.3389/fnmol.2017.00046. eCollection 2017.

32.

Deficits in the activity of presynaptic γ-aminobutyric acid type B receptors contribute to altered neuronal excitability in fragile X syndrome.

Kang JY, Chadchankar J, Vien TN, Mighdoll MI, Hyde TM, Mather RJ, Deeb TZ, Pangalos MN, Brandon NJ, Dunlop J, Moss SJ.

J Biol Chem. 2017 Apr 21;292(16):6621-6632. doi: 10.1074/jbc.M116.772541. Epub 2017 Feb 17.

33.

Discovery of VU0467485/AZ13713945: An M4 PAM Evaluated as a Preclinical Candidate for the Treatment of Schizophrenia.

Wood MR, Noetzel MJ, Melancon BJ, Poslusney MS, Nance KD, Hurtado MA, Luscombe VB, Weiner RL, Rodriguez AL, Lamsal A, Chang S, Bubser M, Blobaum AL, Engers DW, Niswender CM, Jones CK, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

ACS Med Chem Lett. 2016 Dec 16;8(2):233-238. doi: 10.1021/acsmedchemlett.6b00461. eCollection 2017 Feb 9.

34.

The impact of Disrupted-in-Schizophrenia 1 (DISC1) on the dopaminergic system: a systematic review.

Dahoun T, Trossbach SV, Brandon NJ, Korth C, Howes OD.

Transl Psychiatry. 2017 Jan 31;7(1):e1015. doi: 10.1038/tp.2016.282. Review.

35.

Effects of environmental risks and polygenic loading for schizophrenia on cortical thickness.

Neilson E, Bois C, Gibson J, Duff B, Watson A, Roberts N, Brandon NJ, Dunlop J, Hall J, McIntosh AM, Whalley HC, Lawrie SM.

Schizophr Res. 2017 Jun;184:128-136. doi: 10.1016/j.schres.2016.12.011. Epub 2016 Dec 15.

36.

Challenges in the development of an M4 PAM in vivo tool compound: The discovery of VU0467154 and unexpected DMPK profiles of close analogs.

Wood MR, Noetzel MJ, Poslusney MS, Melancon BJ, Tarr JC, Lamsal A, Chang S, Luscombe VB, Weiner RL, Cho HP, Bubser M, Jones CK, Niswender CM, Wood MW, Engers DW, Brandon NJ, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2017 Jan 15;27(2):171-175. doi: 10.1016/j.bmcl.2016.11.086. Epub 2016 Nov 30.

37.

Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits.

Trossbach SV, Bader V, Hecher L, Pum ME, Masoud ST, Prikulis I, Schäble S, de Souza Silva MA, Su P, Boulat B, Chwiesko C, Poschmann G, Stühler K, Lohr KM, Stout KA, Oskamp A, Godsave SF, Müller-Schiffmann A, Bilzer T, Steiner H, Peters PJ, Bauer A, Sauvage M, Ramsey AJ, Miller GW, Liu F, Seeman P, Brandon NJ, Huston JP, Korth C.

Mol Psychiatry. 2016 Nov;21(11):1561-1572. doi: 10.1038/mp.2015.194. Epub 2016 Jan 12.

38.

Balanced translocation linked to psychiatric disorder, glutamate, and cortical structure/function.

Thomson PA, Duff B, Blackwood DH, Romaniuk L, Watson A, Whalley HC, Li X, Dauvermann MR, Moorhead TW, Bois C, Ryan NM, Redpath H, Hall L, Morris SW, van Beek EJ, Roberts N, Porteous DJ, St Clair D, Whitcher B, Dunlop J, Brandon NJ, Hughes ZA, Hall J, McIntosh A, Lawrie SM.

NPJ Schizophr. 2016 Aug 10;2:16024. doi: 10.1038/npjschz.2016.24. eCollection 2016.

39.

SUMOylation of DISC1: a potential role in neural progenitor proliferation in the developing cortex.

Tankou S, Ishii K, Elliott C, Yalla KC, Day JP, Furukori K, Kubo KI, Brandon NJ, Tang Q, Hayward G, Nakajima K, Houslay MD, Kamiya A, Baillie G, Ishizuka K, Sawa A.

Mol Neuropsychiatry. 2016 May;2(1):20-27. Epub 2016 Mar 15.

40.

Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.

Wood MR, Noetzel MJ, Tarr JC, Rodriguez AL, Lamsal A, Chang S, Foster JJ, Smith E, Chase P, Hodder PS, Engers DW, Niswender CM, Brandon NJ, Wood MW, Duggan ME, Conn PJ, Bridges TM, Lindsley CW.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4282-6. doi: 10.1016/j.bmcl.2016.07.042. Epub 2016 Jul 21.

41.

A human-specific AS3MT isoform and BORCS7 are molecular risk factors in the 10q24.32 schizophrenia-associated locus.

Li M, Jaffe AE, Straub RE, Tao R, Shin JH, Wang Y, Chen Q, Li C, Jia Y, Ohi K, Maher BJ, Brandon NJ, Cross A, Chenoweth JG, Hoeppner DJ, Wei H, Hyde TM, McKay R, Kleinman JE, Weinberger DR.

Nat Med. 2016 Jun;22(6):649-56. doi: 10.1038/nm.4096. Epub 2016 May 9.

PMID:
27158905
42.

Compromising KCC2 transporter activity enhances the development of continuous seizure activity.

Kelley MR, Deeb TZ, Brandon NJ, Dunlop J, Davies PA, Moss SJ.

Neuropharmacology. 2016 Sep;108:103-10. doi: 10.1016/j.neuropharm.2016.04.029. Epub 2016 Apr 21.

43.

Biallelic Mutations in PDE10A Lead to Loss of Striatal PDE10A and a Hyperkinetic Movement Disorder with Onset in Infancy.

Diggle CP, Sukoff Rizzo SJ, Popiolek M, Hinttala R, Schülke JP, Kurian MA, Carr IM, Markham AF, Bonthron DT, Watson C, Sharif SM, Reinhart V, James LC, Vanase-Frawley MA, Charych E, Allen M, Harms J, Schmidt CJ, Ng J, Pysden K, Strick C, Vieira P, Mankinen K, Kokkonen H, Kallioinen M, Sormunen R, Rinne JO, Johansson J, Alakurtti K, Huilaja L, Hurskainen T, Tasanen K, Anttila E, Marques TR, Howes O, Politis M, Fahiminiya S, Nguyen KQ, Majewski J, Uusimaa J, Sheridan E, Brandon NJ.

Am J Hum Genet. 2016 Apr 7;98(4):735-43. doi: 10.1016/j.ajhg.2016.03.015.

44.

Searching for cognitive enhancement in the Morris water maze: better and worse performance in D-amino acid oxidase knockout (Dao(-/-)) mice.

Pritchett D, Taylor AM, Barkus C, Engle SJ, Brandon NJ, Sharp T, Foster RG, Harrison PJ, Peirson SN, Bannerman DM.

Eur J Neurosci. 2016 Apr;43(7):979-89. doi: 10.1111/ejn.13192. Epub 2016 Mar 23.

45.

Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models.

Haggarty SJ, Silva MC, Cross A, Brandon NJ, Perlis RH.

Mol Cell Neurosci. 2016 Jun;73:104-15. doi: 10.1016/j.mcn.2016.01.011. Epub 2016 Jan 28. Review.

46.

Early postnatal GABAA receptor modulation reverses deficits in neuronal maturation in a conditional neurodevelopmental mouse model of DISC1.

Saito A, Taniguchi Y, Rannals MD, Merfeld EB, Ballinger MD, Koga M, Ohtani Y, Gurley DA, Sedlak TW, Cross A, Moss SJ, Brandon NJ, Maher BJ, Kamiya A.

Mol Psychiatry. 2016 Oct;21(10):1449-59. doi: 10.1038/mp.2015.203. Epub 2016 Jan 5.

47.

Identification of Phosphorylation Consensus Sequences and Endogenous Neuronal Substrates of the Psychiatric Risk Kinase TNIK.

Wang Q, Amato SP, Rubitski DM, Hayward MM, Kormos BL, Verhoest PR, Xu L, Brandon NJ, Ehlers MD.

J Pharmacol Exp Ther. 2016 Feb;356(2):410-23. doi: 10.1124/jpet.115.229880. Epub 2015 Dec 8.

PMID:
26645429
48.

Compromising the phosphodependent regulation of the GABAAR β3 subunit reproduces the core phenotypes of autism spectrum disorders.

Vien TN, Modgil A, Abramian AM, Jurd R, Walker J, Brandon NJ, Terunuma M, Rudolph U, Maguire J, Davies PA, Moss SJ.

Proc Natl Acad Sci U S A. 2015 Dec 1;112(48):14805-10. doi: 10.1073/pnas.1514657112. Epub 2015 Nov 16.

49.

State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 - Relation to antipsychotic-like drug effects.

Gould RW, Nedelcovych MT, Gong X, Tsai E, Bubser M, Bridges TM, Wood MR, Duggan ME, Brandon NJ, Dunlop J, Wood MW, Ivarsson M, Noetzel MJ, Daniels JS, Niswender CM, Lindsley CW, Conn PJ, Jones CK.

Neuropharmacology. 2016 Mar;102:244-53. doi: 10.1016/j.neuropharm.2015.11.016. Epub 2015 Nov 23.

50.

The cellular target of antidepressants.

Brandon NJ, McKay R.

Nat Neurosci. 2015 Nov;18(11):1537-8. doi: 10.1038/nn.4144. No abstract available.

PMID:
26505563

Supplemental Content

Loading ...
Support Center